Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 35.3% from a year ago

Total equity stood at $250.04M at the end of Q1 FY2026, up 35.3% from a year earlier and down 4.2% from the prior quarter. Over 3 fiscal years it compounded at +88.0% a year.

Context

  • Total equity amounted to 95.7% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +35.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$250.04M-4.2% QoQ
Last fiscal yearDec 2025
$260.99M+31.8% YoY
Year agoMar 2025
$184.77M+35.3% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.3%——
1 year+31.8%——
3-year CAGR+88.0%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
260.99M USD
Year-over-year change
+31.8%
4-year CAGR
+43.5%

Total Equity vs competitors

How CTNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +35.3% is the 5th highest of 8, against a peer median of +65.0%.
  • Total equity amounts to 95.7% of total assets for CTNM, versus a peer median of 94.8%.
CTNM Competitors
Total Equity for CTNM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAPPRapport Therapeutics, Inc. Common StockMar 2026$471.51M USD+65.0%+191.8%94.8%
MPLTMapLight Therapeutics, Inc.Mar 2026$399.83M USD+330.0%+180.0%95.5%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$378.69M USD+3546.2%—96.2%
GHRSGH Research PLCMar 2026$263.38M USD-15.1%+3.8%95.7%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$250.04M USD+35.3%+88.0%95.7%
ANROAlto Neuroscience, Inc.Mar 2026$243.37M USD+75.0%—88.1%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$70.68M USD-69.0%—45.9%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding CTNM) —+65.0%+91.9%94.8%

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.63M5.57M15.53M21.94M75.6M
Short-term Investments64.37M41.67M109.66M182.82M187.29M
Net Receivables00000
Inventory00000
Other Current Assets775K1.15M2.52M1.63M5.02M
Total Current Assets69.78M48.39M127.71M206.39M267.92M
Property, Plant & Equipment (Net)642K2.12M1.4M6.46M8.47M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets97K129K1.28M3K256K
Total Non-current Assets739K2.24M2.68M6.46M8.73M
Total Assets70.52M50.64M130.39M212.85M276.64M
Account Payables660K430K635K1.81M1.02M
Short-term Debt1.25M3.95M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities79K1.31M2.48M3.37M1.59M
Total Current Liabilities3.67M7.55M5.48M9.97M9.74M
Long-term Debt3.66M0192.62M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.6M3.03M110K00
Total Non-current Liabilities5.26M3.82M192.84M4.81M5.91M
Total Liabilities8.93M11.37M198.32M14.78M15.65M
Common Stock12K12K2K26K37K
Retained Earnings(73.61M)(97.86M)(75.14M)(117.4M)(177.38M)
Accumulated OCI(35K)(76K)108K71K260K
Other Stockholders Equity(0)(0)000
Minority Interest00000
Total Equity61.59M39.27M(67.94M)198.07M260.99M
Total Debt4.91M5.85M193.19M6.26M8.25M
Net Debt279K280K177.67M(15.68M)(67.35M)

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.